The 30-second summary
- STRIDE measured walking distance, which almost no obesity trial does, in 792 people with type 2 diabetes and peripheral artery disease.
- Semaglutide improved maximum walking distance at 52 weeks, with an estimated treatment ratio of 1.13 against placebo.
- Everyone in the trial had type 2 diabetes. Whether it holds without diabetes is explicitly unanswered.
- Why it worked was not measured, and the trial was funded by the manufacturer.
- Leg pain that arrives at a predictable distance and settles with rest is worth naming to your prescriber.
What the condition is
Peripheral artery disease is atherosclerosis in the legs: the same furring of arteries that causes heart attacks, in a different place. It is estimated to affect more than 230 million people worldwide.
Its typical symptom, intermittent claudication, is specific enough to recognise. Cramping or aching pain in the calf, thigh or buttock, which comes on after a fairly reliable distance of walking, gets worse if you keep going, and eases within a few minutes of standing still. Then it comes back at about the same distance next time.
People routinely attribute this to age, weight or being unfit, and it often goes unmentioned for years. It matters for two reasons: it narrows life considerably, because the distance you can walk determines where you can go, and it is a marker that the same process is likely happening in arteries elsewhere.
Few treatments improve how far someone can actually walk. That is what makes this trial worth a page.
What STRIDE did
STRIDE was a double-blind, randomised, placebo-controlled trial at 112 sites in 20 countries across North America, Asia and Europe, running from October 2020 to July 2024.
It enrolled adults with type 2 diabetes and peripheral artery disease with intermittent claudication, at Fontaine stage IIa, meaning able to walk more than 200 m, with an ankle-brachial index of 0.90 or less or a toe-brachial index of 0.70 or less. Those are objective measurements of reduced blood flow rather than self-reported symptoms.
792 people were randomised, 396 to once-weekly subcutaneous semaglutide 1.0 mg and 396 to placebo, for 52 weeks. The median age was 68, and 75% were men.
The primary endpoint was the ratio of maximum walking distance at week 52 to the distance at the start, measured on a constant-load treadmill.
| Group | Median ratio to baseline | |
|---|---|---|
| Semaglutide | 1.21 (IQR 0.95 to 1.55) | |
| Placebo | 1.08 (IQR 0.86 to 1.36) | |
| Estimated treatment ratio | 1.13 (95% CI 1.06 to 1.21) | p = 0.0004 |
Safety was unremarkable. Six serious adverse events in five semaglutide participants and nine in six placebo participants were judged possibly or probably treatment related, most commonly gastrointestinal. There were no treatment-related deaths.
Reading the number honestly
A treatment ratio of 1.13 means the semaglutide group improved about 13% more than placebo did, on top of an improvement placebo also showed.
Notice that placebo improved too, at a median ratio of 1.08. Some of that is the ordinary effect of being in a trial: being watched, being weighed, walking on a treadmill every few months. It is a reminder that the drug effect is the gap between the groups, not the change you experience.
Notice also the spread. The interquartile range for semaglutide runs from 0.95 to 1.55, meaning a quarter of people in that group did not improve at all and a quarter improved by more than half. A median is not a promise.
And the honest limitations, which the authors state. Everyone had type 2 diabetes, so the result does not transfer to people with peripheral artery disease and no diabetes without being tested. The mechanism was not investigated, and the authors named it as a research need. The trial was funded by Novo Nordisk, which does not invalidate a double-blind randomised design with an objective endpoint, and is worth knowing.
Why walking distance is the right thing to measure
Most trials in this field measure weight, HbA1c or events. Those matter, and none of them is what a person notices.
What people notice is whether they can get to the shop and back, walk the dog without stopping, or get through an airport. Maximum walking distance on a treadmill is an imperfect proxy for that and it is far closer than a number on a scale.
This is the same argument behind the sit-to-stand test appearing in body composition work: function is the outcome that matters, and it is measured far less often than it should be. A result that says someone can walk further is a different kind of finding from one that says they weigh less.
What it means for you
If you get leg pain when you walk, say so. Particularly if it arrives at a predictable distance and settles with rest. It is easy to attribute to weight or age, it is a specific pattern, and there are tests that take minutes.
If you already have a diagnosis and type 2 diabetes, this is a trial result worth taking to your appointment, in the terms it actually supports: 52 weeks, 1.0 mg, 13% more improvement than placebo, in people like the ones enrolled.
If you have peripheral artery disease and no diabetes, this does not yet apply to you. Say the sentence anyway, because your prescriber will know what is and is not established.
Do not stop your existing treatment. Supervised exercise programmes, blood pressure control, statins and stopping smoking all have established evidence in claudication. A GLP-1 is not a replacement for any of them.
Protect the muscle that does the walking. If your walking distance is limited by your arteries, losing leg muscle on top of it makes everything harder. Protein and resistance work are not optional here; they are the part that preserves the thing being measured.
What to do with this
Walking further requires legs that still have muscle on them. The protein floor is what decides how much of your weight loss comes out of fat rather than out of the muscle you are trying to use.
Sources
- Bonaca MP, et al. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet 2025. PubMed
- Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics. Diabetes Care 2025. PubMed
- Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial. J Am Coll Cardiol 2025. PubMed
- Semaglutide and Limb Events: Expanding the Cardiovascular Prevention Paradigm? Eur J Prev Cardiol 2026. PubMed
Medical disclaimer: Articles in the foodose research library are educational, not medical advice. Follow the instructions from your prescriber and the leaflet in your pack. See our full medical disclaimer.